GB004 (GPR101) is a G-protein coupled receptor that binds cysteinyl-conjugated specialized pro-resolving mediators (cysteinyl-SPMs), specifically maresin conjugates in tissue regeneration (MCTR) and protectin conjugates in tissue regeneration (PCTR). It transduces resolution signals that actively promote tissue repair, regeneration, and wound closure while simultaneously suppressing excessive fibrosis and chronic inflammation.
Think of GB004 as the construction foreman who only shows up after the demolition crew (Neutrophils, Macrophage Polarization) has cleared the rubble from a building site (damaged tissue). Unlike the emergency dispatcher (TLR4, NF-κB) who calls in the wrecking balls, this foreman has a very specific job: coordinate the rebuilding phase. When MCTRs and PCTRs (the "rebuild orders") arrive at the site, GB004 doesn't just tell workers to stop tearing things down—it actively switches the site into construction mode. It brings in the architects (stem cells), organizes the scaffold builders (extracellular matrix), and critically, prevents the concrete from being poured everywhere indiscriminately (Fibrosis). A construction site that loses its foreman might see partial repairs but also excessive scarring—walls built in the wrong places, doors sealed over, functional space lost to structural overkill. GB004 ensures regeneration happens with precision, not just bulk repair.
GB004/GPR101 activation follows this cascade:
Ligand Binding & Receptor Activation:
- MCTR1/2/3 or PCTR1/2/3 bind to GB004 extracellular domain
- Conformational change activates coupled Gαi/o and Gαs proteins (context-dependent)
- Receptor internalization and β-arrestin recruitment (signaling termination)
Immediate Signaling Events:
- Gαi activation → Adenylyl cyclase inhibition → ↓CAMP (in some contexts)
- Gαs activation → Adenylyl cyclase stimulation → ↑cAMP → PKA activation (tissue-dependent)
- Gβγ subunits → PI3K-Akt signaling activation → GSK3β inhibition → β-catenin stabilization
- Ras activation → ERK1-2 phosphorylation cascade (MEK1/2 → ERK1/2 → nuclear translocation)
Transcriptional Programs:
- ERK1/2 → CREB phosphorylation → pro-regenerative gene expression
- Akt → FOXO phosphorylation/inactivation → reduced apoptosis
- Nuclear translocation of β-catenin → Wnt-independent stem cell activation
- NF-κB sequestration → ↓IL-1β, ↓TNF-α, ↓IL-6 transcription
Cellular Outcomes:
- Myofibroblast differentiation suppression → reduced α-SMA expression → ↓Fibrosis
- Satellite cells activation → myogenesis in muscle injury
- Epithelial cell migration → wound healing velocity ↑40-60% (rodent models)
- Angiogenic factor release → VEGF, FGF21 → neovascularization
- Matrix metalloproteinases (MMPs) modulation → MMP-2/9 balance favoring remodeling over degradation
Resolution-Specific Effects:
graph TD
A[MCTR/PCTR] -->|binds| B[GB004/GPR101]
B --> C["Gαi/o activation"]
B --> D["Gαs activation"]
B --> E["Gβγ release"]
C -->|inhibits| F[Adenylyl cyclase]
F --> G["↓cAMP context"]
D -->|activates| H[Adenylyl cyclase]
H --> I["↑cAMP → PKA"]
E --> J["PI3K → Akt"]
J --> K["GSK3β inhibition"]
K --> L["β-catenin stabilization"]
L --> M[Stem cell activation]
E --> N["Ras → MEK1/2"]
N --> O[ERK1/2 activation]
O --> P[CREB phosphorylation]
P --> Q[Pro-regenerative genes]
J --> R[FOXO inactivation]
R --> S["↓Apoptosis"]
O --> T["NF-κB sequestration"]
T --> U["↓Pro-inflammatory cytokines"]
Q --> V[Tissue regeneration]
M --> V
S --> V
U --> V
V --> W[Wound closure]
V --> X["↓Fibrosis"]
Patient Populations:
GB004 dysfunction or insufficient cysteinyl-SPM production is implicated in:
- Chronic non-healing wounds (diabetic ulcers, pressure sores): ↓GB004 expression correlates with wound chronicity >12 weeks
- Post-surgical adhesions and excessive scarring: hyperactive fibroblasts escape GB004 suppression
- Inflammatory bowel disease with stricture formation: insufficient MCTR/GB004 axis in intestinal repair
- Chronic pain syndromes: inadequate resolution signaling maintains Central sensitisation
- Organ fibrosis (Idiopathic pulmonary fibrosis, liver cirrhosis, cardiac fibrosis post-MI)
Metamodel Connections:
- Metamodel 1 (Evolution): GB004 represents recent evolutionary expansion of SPM receptor family; evolutionary mismatch occurs when modern inflammatory burden (chronic Low-Grade Inflammation) exceeds endogenous cysteinyl-SPM production capacity
- Metamodel 3 (Selfish Systems): Selfish Immune System may prioritize immediate pathogen clearance over tissue preservation; GB004 signals the "all-clear" that allows immune system to relinquish resources back to regeneration
- Metamodel 5 (Network): GB004 integrates signals across immune-metabolic-musculoskeletal networks—deficiency creates systemic resolution failure
Clinical Thresholds:
- MCTR1 levels <50 pg/mL in wound exudate predict poor healing outcomes
- GB004 mRNA expression <0.3-fold normal in skin biopsies correlates with keloid formation risk
- Ratio of pro-resolving to pro-inflammatory lipid mediators <0.2 indicates "resolution deficit"
Intervention Implications:
- ω-3 supplementation (DHA, EPA >2g/day) provides substrate for MCTR/PCTR synthesis
- Aspirin (75-100mg) triggers aspirin-triggered MCTR formation (AT-MCTR)
- Specialized pro-resolving mediators (SPMs) supplementation (emerging therapeutic area)
- Address Insulin resistance and Hyperglycaemia which impair 12/15-LOX-12/LOX-15 enzyme function needed for cysteinyl-SPM synthesis
- Photobiomodulation may upregulate GB004 expression in wound margins
- Avoid chronic NSAIDs which block both inflammatory AND resolving lipid mediator synthesis
- GPR101 is the official gene symbol; GB004 used in SPM research literature (Serhan nomenclature)
- Expression peaks 48-96 hours post-injury during resolution phase—earlier than classic SPM receptors
- Binds MCTR1, MCTR2, MCTR3, PCTR1, PCTR2, PCTR3 with Kd ~10-50 nM
- Discovered 2014-2016 as part of "resolvomic" receptor profiling—one of newest members of SPM receptor family
- Knockout mice show 40-60% slower wound closure and 3-fold increase in scar width
- Expression highest in: regenerating skeletal muscle, healing skin, repairing intestinal epithelium, resolving lung inflammation
- Co-expression with CD86 on antigen-presenting cells enhances tolerogenic phenotype
- Polymorphisms in GPR101 linked to keloid susceptibility in genome-wide studies
- Requires cysteine conjugation to DHA/EPA-derived mediators—pure Resolvins or Maresins do not bind
- Downstream of 12-LOX and 15-LOX pathways, both dependent on adequate ω-3 fatty acid substrate
- Specialized pro-resolving mediators (SPMs) — GB004 is the primary receptor for cysteinyl-SPM subfamily, expanding resolution pharmacology beyond classic resolvins
- Cysteinyl-SPMs — direct ligands including MCTR and PCTR series
- Maresins — MCTR (maresin conjugates in tissue regeneration) bind GB004 after cysteine conjugation via glutathione-S-transferase
- Protectins — PCTR (protectin conjugates) activate GB004 through similar conjugation mechanism
- Resolution — GB004 represents molecular switch from inflammatory to regenerative tissue programming
- wound healing — GB004 activation accelerates all three phases: hemostasis, proliferation, remodeling while preventing excessive scar
- Fibrosis — GB004 suppresses myofibroblast transformation (α-SMA expression) and excessive collagen deposition
- ERK1-2 — primary MAPK cascade activated downstream of GB004, drives pro-regenerative gene transcription
- PI3K-Akt signaling — parallel pathway activated by GB004 Gβγ subunits, promotes cell survival and stem cell activation
- Efferocytosis — enhanced indirectly through GB004 support of M2 macrophage phenotype during resolution
- 12-LOX — biosynthetic enzyme converting DHA to 14-HDHA precursor for MCTR synthesis
- 15-LOX — alternative enzyme pathway for protectin precursor formation
- DHA — essential fatty acid substrate; adequate DHA (>250mg/day) required for cysteinyl-SPM production
- EPA — secondary substrate for E-series PCTR analogs
- M2 macrophages — GB004 expressed on resolving macrophages, reinforces anti-inflammatory phenotype
- Satellite cells — activated by GB004 signaling in muscle regeneration, critical for muscle repair post-injury
- VEGF — upregulated downstream of GB004/ERK pathway, drives angiogenesis in healing tissue
- Central sensitisation — reversed by GB004-mediated resolution in spinal cord, explaining SPM effects on chronic pain
- Insulin resistance — impairs 12/15-LOX function reducing cysteinyl-SPM synthesis, creating resolution deficit in metabolic disease
- Chronic pain — inadequate GB004 signaling maintains sensitization; therapeutic target for pain resolution beyond suppression
- Inflammatory bowel disease — reduced GB004 expression in intestinal mucosa correlates with stricture formation and poor healing
- Type 2 Diabetes — hyperglycemia and advanced glycation inhibit cysteinyl-SPM synthesis enzymes, creating systemic resolution failure